KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Emergent BioSolutions (EBS) over the last 16 years, with Q3 2025 value amounting to $23.4 million.

  • Emergent BioSolutions' Depreciation & Amortization (CF) fell 1136.36% to $23.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $98.3 million, marking a year-over-year decrease of 1254.45%. This contributed to the annual value of $108.8 million for FY2024, which is 1302.96% down from last year.
  • According to the latest figures from Q3 2025, Emergent BioSolutions' Depreciation & Amortization (CF) is $23.4 million, which was down 1136.36% from $23.5 million recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Depreciation & Amortization (CF) registered a high of $44.5 million during Q2 2022, and its lowest value of $23.4 million during Q3 2025.
  • For the 5-year period, Emergent BioSolutions' Depreciation & Amortization (CF) averaged around $30.2 million, with its median value being $29.2 million (2021).
  • As far as peak fluctuations go, Emergent BioSolutions' Depreciation & Amortization (CF) soared by 3403.61% in 2022, and later tumbled by 2606.74% in 2023.
  • Over the past 5 years, Emergent BioSolutions' Depreciation & Amortization (CF) (Quarter) stood at $29.2 million in 2021, then grew by 22.26% to $35.7 million in 2022, then decreased by 17.09% to $29.6 million in 2023, then dropped by 12.16% to $26.0 million in 2024, then decreased by 10.0% to $23.4 million in 2025.
  • Its Depreciation & Amortization (CF) was $23.4 million in Q3 2025, compared to $23.5 million in Q2 2025 and $25.4 million in Q1 2025.